ArriVent Posts $93.2M Net Loss, Cash Runway Into 2028; FURVENT Data Due 2H 2026
AVBP sits 95% above its 52-week low of $16.1.
Summary
ArriVent reported Q2 2026 results with a net loss of $93.2M for the first half, slightly improved from $95.8M a year ago. Cash and investments stand at $373.1M, expected to fund operations into 2028. The company initiated Phase 1b dose optimization for its ADC lead ARR-217 and signed a Greater China license deal with Allist for ARR-002. Key upcoming catalysts include topline data from the pivotal FURVENT Phase 3 trial for firmonertinib in EGFR exon 20 insertion NSCLC in 2H 2026, initial Phase 1 data for ARR-217, and first patient dosing for ARR-002 in Q3 2026. The financials are in line with expectations for a clinical-stage biotech, but the FURVENT readout is the major binary event that could significantly move the stock.
At the time of this announcement, AVBP was trading at $31.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $16.10 to $35.83. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.